

YoungSuk 'Y.S.' Chi

Chairman, Elsevier Management Committee

Fiesole Collection Development Retreat
National Library of Russia
St. Petersburg, Russia
May 2011



My visit to Russia




Russian research history



Lomonosov



Mendeleev




Pavlov


The lamplighter...



Publishers and librarians provide support




Publishers are well-positioned to help





The roles that publishers and librarians have traditionally filled are delineated and defined.



Output is increasing around the globe







The developing world is quickly rising



ELSEVIER

Research is growing interdisciplinary



Technology impacts the way we live




Key findings from engagement

Finding # 1

Researchers need more targeted tools

SciVerse enables more functionality




Elsevier's flagship products connected and accessed via a single, central hub

API enables third-party developers to build additional functionality on top of centralized content

What we do have evolved significantly

Originally...



Farmed high-quality content



Before...



Created a super-market for content acquisition



Today...




Prepare fine meals to meet the tastes of groups of or individual researchers

New tools to better serve researchers



SciVerse enables more functionality



Applications enable more functionality

The image displays two overlapping screenshots from a web application. The left screenshot shows the 'My Applications' dashboard with a list of applications including 'My Oncology Articles'. The right screenshot shows the 'My Oncology Articles' settings page, which includes a 'Tumor Types' section with a list of cancer types and checkboxes, and a 'Journal Set' section.

My Oncology Articles

Settings

Tumor Types

Select All

- Bladder
- Breast
- Colon and Rectum
- Esophagus
- Head and Neck
- Kidney (Renal Cell)
- Liver and Bile Duct
- Multiple Myeloma
- Myeloproliferative Diseases
- Pancreas
- Prostate
- Skin
- Stomach
- Bone
- CNS/Brain
- Endocrine System
- Gynecology
- Hodgkin's Lymphoma
- Leukemia
- Lung
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma
- Pediatric Cancers
- Rare Cancers
- Soft-Tissue Sarcoma
- Testicle

Journal Set

Article Type

Save Cancel

My Oncology Articles enables oncologists and relevant medical researchers to track content that is important to them.

Key findings from engagement

Realization # 1

Researchers need more targeted tools

Realization # 2

Researchers need more from their content

New article formats are essential today

Cell -- Hantschel et al.
http://www.cell.com/content/article/abstract/uid=PIIS0092

Cell

Home Search Archive
Email Alerts RSS Help
Register Login Password

Title/abstract/keywords Author

LNA-based microRNA PCR system

Copyright © 2003 Cell Press.
Cell, Vol 112, 845-857, 21 March 2003

Article

A Myristoyl/Phosphotyrosine Switch Regulates c-Abl

Oliver Hantschel,^{1,5} Bhushan Nagar,^{2,5} Sebastian Guettler,¹ Jana Kretzschmar,¹ Karel Dorey,^{1,6} John Kuriyan,^{3,4} and Giulio Superti-Furga^{1,2}

¹Developmental Biology Programme, European Molecular Biology Laboratory, 69117 Heidelberg, Germany
²Cellzome AG, Meyernofstrasse 1, 69117 Heidelberg, Germany
³Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720 USA
⁴Physical Biosciences Division, Lawrence Berkeley National Lab, Berkeley, CA 94720 USA

*Corresponding author
Giulio Superti-Furga
+49 6221-137 57 113 (phone)
+49 6221-137 57 210 (fax)

Summary

The **c-Abl** tyrosine kinase is inhibited by mechanisms that are poorly understood. Disruption of these mechanisms in the **Bcr-Abl** oncoprotein leads to several forms of human leukemia. We found that like **Src** kinases, **c-Abl** 1b is activated by phosphotyrosine ligands. Ligand-activated **c-Abl** is particularly sensitive to the anti-cancer drug **STI-571** / **Gleevec/imatinib** (STI-571). The SH2 domain-phosphorylated tail interaction in **Src** kinases is functionally replaced in **c-Abl** by an intramolecular engagement of the N-terminal myristoyl modification with the kinase domain. Functional studies coupled with structural analysis define a myristoyl/phosphotyrosine switch in **c-Abl** that regulates docking and accessibility of the SH2 domain. This mechanism offers an explanation for the observed cellular activation of **c-Abl** by tyrosine-phosphorylated proteins, the intracellular mobility of **c-Abl**, and it provides new insights into the mechanism of action of **STI-571**.

Reflect - SRC

Protein Chemical Other

▼ Rous sarcoma oncogene ▼ Homo sapiens [edit]

SRC, SRC1, p60-Src, c-Src, pp60c-src, ...

Sequence, Locus, Pathways, Diseases, Literature, Patents

Src is a family of proto-oncogenic tyrosine kinases originally discovered by J. Michael Bishop and Harold E. Varmus, for which they won the ...

Reflect - Imatinib

Chemical Protein Other

Gleevec; Glivec [edit]

Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as **Gleevec** (USA) or **Glivec** (Europe/Australia) as its mesylate salt, **imatinib mesilate** (INI). It was originally coded during development as CGP571488 or STI-571 (these terms are used in early preclinical publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

The Article of the Future initiative leverages technology to enable researchers to get more out of each of the articles they read. Pilots are running in several Elsevier journals.

Key findings from engagement

Realization # 1

Researchers need more targeted tools


Realization # 2

Researchers need more from their content

Realization # 3

Researchers need help planning increasingly competitive research environments

More analysis is needed to manage well



SciVal Spotlight allows researcher managers to visualize their research environments, identify distinctive and emerging research competencies, and plan for how to develop them

More analysis is needed to manage well

Rankings

Rank	Institution	Weight
1	Athena University	130.61
2	University of Birmingham	108.49
3	University of Oxford	82.94
4	University of Bristol	62.66
5	University of Cambridge	60.62
6	Queen's University Belfast	50.71
7	University of Manchester	50.08
8	Imperial College London	48.55
9	Cardiff University	47.94
10	University of Edinburgh	43.20

Market Share Trend

Institution	Growth
Athena University	0.37%
University of Birmingham	0.09%
University of Oxford	0.12%
University of Bristol	0.02%
University of Cambridge	0.26%
Queen's University Belfast	-0.18%
University of Manchester	0.13%
Imperial College London	0.14%
Cardiff University	0.19%
University of Edinburgh	-0.28%

Key Researchers

ORG	Author	npar	Weight
Athena University	Smith, A	4	28.66
Athena University	Smith, B	2	13.06
Athena University	Smith, C	7	11.08
Athena University	Smith, D	14	10.13
Athena University	Smith, E	1	9.14
Athena University	Smith, F	10	8.39
Athena University	Smith, G	6	6.76
Athena University	Smith, H	5	6.11

Key Competitors

ORG	Author	npar	Weight
Newcastle University	Brown, A	1	10.63
University of Liverpool	Brown, B	3	10.03
University of Oxford	Brown, C	1	9.38
University of Nottingham	Brown, D	3	8.53
University of Manchester	Brown, E	6	7.38
Queen's University Belfast	Brown, F	9	7.14
University of Sheffield	Brown, G	2	6.99
University of Warwick	Brown, H	6	6.53

SciVal Spotlight also allows research managers to look at their research environments with the context of comparison.



The lamplighter revisited...



Serving the scholarly community



ELSEVIER